TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03551340

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastro-intestinal panel by PCR
Description: The study will evaluate the change in medical management with the replacement of traditional stool investigations (microscopy and culture) by the new gastrointestinal multiplex PCR panels
Study: NCT04957498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help for Family Based Treatment
Description: A online website provided to parents containing information learned in Family Based Treatment and up to 12 coaching sessions with a therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Treatment
Description: Standard Family Based Treatment provided for up to 15 sessions.
Study: NCT04372355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WF10
Description: WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks.
Study: NCT03898583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microarray patch A
Description: Microarray patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microarray patch B
Description: Microarray patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microarray patch vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet
Description: Daivobet Gel
Study: NCT03634046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous transforaminal endoscopic discectomy
Description: The same as the descriptions in experimental group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: The same as the descriptions in active comparator group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: The same as the descriptions in active comparator group.
Study: NCT02383719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oro-nasal Mask
Study: NCT04398706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine formulation 3
Description: Pharmaceutical form:liquid Route of administration: intramuscular
Study: NCT01899144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Spiromax
Description: Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Spiromax
Description: Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
Study: NCT02807805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study: NCT02563834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiapalmitate tracer
Description: Radiolabeled tracer infusion; occurs in all treatment arms
Study: NCT01899144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProAir HFA
Description: ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProAir HFA
Description: ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
Study: NCT04398706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine formulation 3
Description: Pharmaceutical form:liquid Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Virus Vaccine Live
Description: Pharmaceutical form:liquid Route of administration: subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Virus Vaccine Live
Description: Pharmaceutical form:liquid Route of administration: subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Virus Vaccine Live
Description: Pharmaceutical form:liquid Route of administration: subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella Virus Vaccine Live
Description: Pharmaceutical form:liquid Route of administration: subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, and Rubella Virus Vaccine Live
Description: Pharmaceutical form:liquid Route of administration: subcutaneous
Study: NCT02563834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiapalmitate tracer
Description: Radiolabeled tracer infusion; occurs in all treatment arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline infusion for control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin infusion for insulin/glucose clamp procedure
Study: NCT04357002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous tranexamic acid
Description: patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal dinoprostone
Description: patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vaginal placebo
Description: patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
Study: NCT01899144

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
Study: NCT03804034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Block of resin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Block of resin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buccal tube, Bracket and 0.0017 × 0.025 in titanium molybdenum alloy wire

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buccal tube, Bracket and 0.0017 × 0.025 in titanium molybdenum alloy wire
Study: NCT02851186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Study: NCT04337385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interrupting 3 hours of prolonged sitting with high intensity interval exercise
Description: Breaking up a prolonged bout of sitting in adolescents using high intensity interval exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 hours of prolonged sitting
Description: Participants will be asked to remain seated for 3 hours and refrain from moving their lower limbs
Study: NCT03224546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Subjects will receive payments for providing cocaine negative urine samples.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Subjects will receive payments for providing cocaine negative urine samples.
Study: NCT03461510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperglycemic clamp
Description: Subjects with T2D will receive IV Dextrose infusion to maintain plasma glucose at \~250 mg/dL during fMRI.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic Euglycemic clamp
Description: Subjects with T2D will receive IV Dextrose and Insulin infusion to maintain plasma glucose at approximately 90 mg/dL during fMRI.
Study: NCT04140136

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tocotrienols
Description: Tocotrienols as a potent antioxidant to modulate oxidative stress and inflammatory response

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is similar in appearance, but does not contain tocotrienols and consist of palm oil
Study: NCT01776385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
Study: NCT04639115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod
Study: NCT03020290

Intervention type: DEVICE
Intervention: Endovascular treatment for PAD during medical care (SuperA stent (Abbott))
Description: Long femoropopliteal stenting with SuperA devices during medical care. The endovascular treatment for PAD will be done during the usual medical treatment of patient. The intervention is not carried out within the framework of the research protocol
Study: NCT02776371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified non-clarithromycin triple therapy
Description: H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential therapy
Description: H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
Study: NCT00785967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Various vaccines
Description: VAQTA: 1.0ml IM at weeks 24 \& 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Various vaccines
Description: VAQTA: 1.0ml IM at weeks 24 \& 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
Study: NCT04490031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: patient in Ketamine group will be given Ketamine as sedative agent
Study: NCT00553865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OJP-2028
Description: Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OJP-2028
Description: Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OJP-2028
Description: Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OJP-2028
Description: Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: OJP-2028
Description: Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
Study: NCT01328171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI + Panitumumab
Description: irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOXIRI
Description: irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Study: NCT04798807

Intervention type: DIAGNOSTIC_TEST
Intervention: Nutritional screening
Study: NCT03930160

Intervention type: OTHER
Intervention: Logistic Organ Dysfunction System Score
Description: Variables of logistic organ dysfunction system score, including: GCS; heart rate; systolic BP; blood urea; serum creatinine; urine output; leucocyte count; platelet count; PaO2/FiO2; serum bilirubin; prothrombin time.
Study: NCT02884843

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation laryngeal Tube Suction
Description: Intubation laryngeal Tube Suction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AuraGain Laryngeal Mask
Description: AuraGain Laryngeal Mask
Study: NCT00589485

Intervention type: DEVICE
Intervention: Simplex® Bone Cement
Description: This arm will utilize Simplex® Bone Cement in total knee replacement.

Intervention type: DEVICE
Intervention: Cobalt™ Bone Cement
Description: This arm utilizes Cobalt™ Bone Cement in total knee replacement.
Study: NCT04398706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Pharmaceutical form:liquid Route of administration: oral

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Pharmaceutical form:liquid Route of administration: oral
Study: NCT03728127

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brazilian cardioprotective diet
Description: Brazilian cardioprotective diet prescription
Study: NCT04398706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine* [Recombinant] *as applicable
Description: Pharmaceutical form:liquid Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine* [Recombinant] *as applicable
Description: Pharmaceutical form:liquid Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine* [Recombinant] *as applicable
Description: Pharmaceutical form:liquid Route of administration: intramuscular
Study: NCT03728127

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brazilian cardioprotective diet plus 30g/day of mixed nuts
Description: Brazilian cardioprotective diet plus 30g/day of nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
Study: NCT04398706

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine* [Recombinant] *as applicable
Description: Pharmaceutical form:liquid Route of administration: intramuscular
Study: NCT01067638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1.0g loading dose before skin incision and continuous infusion 200 mg/h during surgery
Study: NCT01347684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy, splint therapy and physical therapy
Description: Includes patient education, use of a mouth guard, jaw muscle exercises and brief cognitive-behavioral intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard care using current drugs
Description: Standard Drug therapy
Study: NCT03366649

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Undersizing Mitral Annuloplasty
Description: Participants will receive a commercially available annuloplasty ring of the surgeon's choice. Sutures are placed around the mitral annulus, and the metallic ring is then implanted onto the mitral annulus to reduce it in size.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Undersizing Mitral Annuloplasty
Description: Participants will receive a commercially available annuloplasty ring of the surgeon's choice. Sutures are placed around the mitral annulus, and the metallic ring is then implanted onto the mitral annulus to reduce it in size.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Papillary Muscle Approximation
Description: One or two 4-0 pledgeted sutures are used to draw the two papillary muscle tips together to reduce the inter papillary muscle separation (IPMS) before undergoing undersizing mitral annuloplasty.
Study: NCT00939796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acclarent Tympanostomy Tube Delivery System
Description: A device which provides a means to create a myringotomy with insertion of a proloaded tympanostomy tube (TT) for placement of the TT in patients indicated for such treatment for Otitis Media
Study: NCT01676220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE901-U300 (new formulation of insulin glargine)
Description: HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]).
Study: NCT01746602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timoptic® 0.5%
Description: Timoptic® 0.5% Eye Drops, Merck, single instillation
Study: NCT01676220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (insulin glargine)
Description: Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
Study: NCT03869996

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fast track care protocol
Description: fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard care protocol
Description: standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
Study: NCT04147260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match BI 730357
Description: Film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Film-coated tablet
Study: NCT01555021

Intervention type: GENETIC
Intervention: Genotyping assays
Description: Patients will provide blood samples at the beginning of the study. If the patient is in the AGT group (as opposed to the TAU group), their blood samples will be sent for genotyping immediately. AGT psychiatrists will be given the results of genotyping within 3-5 days in order to decide which antidepressants to use long-term and at what doses. Patients in the Treatment as Usual group will have their blood samples stored for future analysis. Both groups will provide saliva samples for GWAS analysis at a alter date; however, since the study was terminated early, GWAS testing for both groups and genotyping for the TAU group were not performed.~Patients will receive questionnaires to measure their mood, side effects, and symptoms.~Patients will be asked to participate in 3 follow-up phone calls (1 month, 3 months, and 6 months) to measure their mood.
Study: NCT03706911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500A-LAI
Description: VM-1500A (parent drug of elsulfavirine) IM injection dosage form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500A-LAI
Description: VM-1500A (parent drug of elsulfavirine) IM injection dosage form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500A-LAI
Description: VM-1500A (parent drug of elsulfavirine) IM injection dosage form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500A-LAI
Description: VM-1500A (parent drug of elsulfavirine) IM injection dosage form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500A-LAI
Description: VM-1500A (parent drug of elsulfavirine) IM injection dosage form
Study: NCT01880554

Intervention type: DEVICE
Group type: OTHER
Intervention: Contrast-enhanced intraoperative ultrasound
Description: Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:~Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages
Study: NCT03355365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrathecal MSC-NP injection
Description: MSC-NPs represent a neural subpopulation of MSCs from bone marrow with reduced pluripotency and minimized risk of ectopic differentiation, thus are likely to be more suitable for CNS delivery. Importantly, characterization of MSC-NPs demonstrated their immunoregulatory and trophic properties, and MSC-NPs derived from MS and non-MS patients alike were therapeutically viable.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intrathecal saline injection
Description: Placebo